Sharemaestro Newsreel

Belite Bio (BLTE) Is Up 12.9% After FDA Priority Review For Tinlarebant In Stargardt Disease

Belite Bio (BLTE) shares increased by 12.9% following the FDA's acceptance and Priority Review designation for its New Drug Application for tinlarebant, aimed at treating Stargardt Disease Type 1. The PDUFA target action date is set for February 12, 2027, and if approved, tinlarebant …

Affinity Asset Advisors (IBIO) discloses 5.07M-share, 9.99% stake in iBio

Affinity Asset Advisors, LLC and Michael Cho have disclosed a beneficial ownership of 5,068,882 shares, representing approximately 9.99%, of iBio, Inc.'s common stock. This includes 1,061,001 shares issuable upon the exercise of warrants, all subject to a 9.99% beneficial ownership limitation. The filing, a …

A Quick Look at Today's Ratings for Annexon(ANNX.US), With a Forecast Between $8 to $27

This article provides an overview of Annexon (ANNX.US) stock ratings from four analysts in the last quarter, with a consensus price target ranging from $8 to $27. The analysts show a generally bullish sentiment, reflected in their diverse ratings and price targets, indicating varying …

Eledon Pharmaceuticals (ELDN) widens Q2 loss while advancing tegoprubart to Phase 3

Eledon Pharmaceuticals reported a wider Q2 2026 net loss of $31.6 million, compared to $11.2 million a year prior, primarily due to a non-cash loss from warrant liability remeasurement. Despite this, the company is advancing its lead drug, tegoprubart, to a global Phase 3 …

Eledon Islet Study: All 12 Patients Reached Insulin Independence

Eledon Pharmaceuticals reported positive second-quarter 2026 financial results and significant clinical progress for its lead anti-CD40L antibody, tegoprubart. A successful End-of-Phase 2 FDA meeting supports a global Phase 3 kidney transplantation trial set to enroll approximately 600 patients in late 2026. Notably, an islet …

Belite Bio (NASDAQ:BLTE) Stock Price Down 7.2% - Should You Sell?

Belite Bio (NASDAQ:BLTE) stock declined 7.2% to $166.11 on Thursday, with trading volume below its average. Despite the drop, analysts have a "Moderate Buy" consensus rating with an average price target of $204.40. The company, a clinical-stage biotechnology firm, reported a narrower-than-expected quarterly loss …

Piper Sandler Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Maintains Target Price $8

Piper Sandler has reiterated its Buy rating on Acrivon Therapeutics (ACRV.US) and maintained its price target at $8. This indicates continued confidence from the firm in the company's financial prospects and stock performance.

Enlivex Ltd. (ENLV) sees 9.99% stake reported via convertible note

Lind Global Asset Management XIV, LLC, The Lind Partners, LLC, and Jeff Easton have reported beneficial ownership of 9.99% of Enlivex Ltd.'s ordinary shares through a Senior Secured Convertible Promissory Note. The note includes a clause preventing conversion that would lead to ownership exceeding …

Kyntra Bio Targets Late-2026 Milestones for Cancer and Anemia Drugs

Kyntra Bio (Nasdaq: KYNB) reported its second-quarter 2026 financial results, highlighting a net income of $12.0 million due to a significant gain from subsidiary deconsolidation. The company finished the quarter with $95.7 million in cash, expected to fund operations into 2028. Key pipeline advancements …

Caribou's Single-Dose CAR-T Shows 92% Response in 12 Myeloma Patients

Caribou Biosciences reported its Q2 2026 financial results and provided an update on its CAR-T pipeline. The company's vispa-cel therapy for large B cell lymphoma showed an 82% overall response rate, while CB-011 for multiple myeloma achieved a 92% overall response rate in a …

Aktis Oncology (AKTS) posts Q2 2026 results with $517M cash runway into 2029

Aktis Oncology reported its Q2 2026 results, highlighting progress in its targeted radiopharmaceutical pipeline with promising early data for AKY-2519 and ongoing trials for AKY-1189. The company maintains a strong financial position with $517.3 million in cash, cash equivalents, and marketable securities, projected to …

Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026

Aktis Oncology reported its financial results and business highlights for the second quarter of 2026, showcasing strong execution and progress in its clinical pipeline. The company presented promising first-in-human clinical imaging and dosimetry data for AKY-2519 and is actively enrolling patients in Phase 1b …

Zentalis Pharmaceuticals stock falls on public offering news

Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) shares dropped 6.5% after announcing an underwritten public stock offering, which will include common stock and pre-funded warrants. The company plans to use the proceeds to fund clinical trials, preclinical studies, regulatory filings, and manufacturing for its oncology programs, particularly …

Mineralys' New Chief Medical Officer Receives 4-Year Equity Awards

Mineralys Therapeutics (Nasdaq: MLYS) announced that its independent directors granted inducement equity awards to newly appointed Chief Medical Officer Dr. Terry Ferguson on August 10, 2026. These awards include a stock option for 135,000 shares and a restricted stock unit (RSU) award for 102,400 …

Affinity Asset Advisors (OVID) discloses 15.1M-share Ovid stake with warrant cap

Affinity Asset Advisors, through its Affinity Healthcare Fund, LP, and Michael Cho, have disclosed a beneficial ownership of 15,143,728 shares of Ovid Therapeutics Inc. common stock, representing 7.9% of the outstanding shares as of June 30, 2026. This stake includes nearly 5 million shares …

Altimmune (ALT) CEO Jerome Durso purchases 15,000 shares at $2.95 each

Altimmune, Inc.'s President and CEO, Jerome Benedict Durso, purchased 15,000 shares of the company's common stock at $2.95 per share on August 13, 2026. This transaction, conducted in the open market or a private transaction, increased his direct holdings to 62,500 shares. The Form …

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Elicio Therapeutics announced its second-quarter 2026 financial results and provided corporate updates, including plans to initiate a Phase 1 combination study of ELI-002 7P for metastatic pancreatic cancer in Q4 2026, following observations of multiple complete responses. While its Phase 2 AMPLIFY-7P trial did …

Akari Therapeutics reports Q2 2026 net loss $4.8M, raises ~$8.6M, advancing AKTX-101 toward mid-2027 Phase 1

Akari Therapeutics reported a net loss of $4.8 million for Q2 2026 and held $7.7 million in cash. The company raised approximately $8.6 million in gross proceeds through a private placement and warrant exercises. Akari is advancing its lead ADC candidate, AKTX-101, towards a …

AXSOME THERAPEUTICS, INC. : MIZUHO RAISES TARGET PRICE TO $316 FROM $306

Mizuho has increased its target price for Axsome Therapeutics, Inc. to $316, up from the previous $306. This adjustment indicates a positive outlook from the analyst firm regarding the biopharmaceutical company's future performance.

Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements

Alumis Inc. reported its second-quarter 2026 financial results, highlighting strong long-term data for envudeucitinib in plaque psoriasis, with 54% of patients achieving complete skin clearance. The company plans to submit a New Drug Application for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026 and …

Abeona Therapeutics (NASDAQ:ABEO) Issues Quarterly Earnings Results, Misses Estimates By $0.12 EPS

Outlook Therapeutics (OTLK) Q3 Earnings Preview: Valuation Chall

ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints

Ascendis Pharma A/S Q2 Earnings Call Highlights

Ascendis Pharma A/S reported strong Q2 2026 results, with total revenue more than doubling year-over-year due to increased demand for its TransCon-based therapies. Yorvipath and Yuviwel showed significant growth and early momentum, respectively, contributing to the company's positive financial outlook. Ascendis also outlined pipeline …

Fractyl Health, Inc. - Common Stock (Nasdaq:GUTS) Stock Quote

This article provides a stock quote for Fractyl Health, Inc. (Nasdaq: GUTS), detailing its current price, daily range, volume, and performance metrics. It also includes recent news headlines and press releases related to the company's financial results, clinical trial updates, and investor events. Key …

Mirum Pharmaceuticals (MIRM) Stock Looks Fairly Valued After Recent News

Mirum Pharmaceuticals (MIRM) stock is currently considered fairly valued despite significant share price gains over the past five years. The company's P/S ratio of 10.4x is below the biotech industry average, suggesting it might still be on the inexpensive side. The future performance of …

CYTK Maintained by Barclays -- Price Target Raised to $110

Barclays has maintained an Overweight rating for Cytokinetics (CYTK) and increased its price target to $110, reflecting a positive outlook despite the company being unprofitable. The stock is considered undervalued by 60.9% according to GF Value™, but its GF Score™ of 51/100 indicates average …

Top trending stocks today: ARX, OMER, TMS lead the market movers

Accelerant Holdings (ARX), Omeros Corporation (OMER), and Teamshares Inc. (TMS) were among the top trending stocks, experiencing significant surges due to major news or earnings momentum. Accelerant Holdings saw a 43.2% jump after an announced all-cash buyout, Omeros Corporation rose 24.5% following impressive Q2 …

Alto Neuroscience stock hits all-time high at 32.74 USD

Alto Neuroscience Inc. (ANRO) stock has reached an all-time high of $32.74, marking a 906.09% increase over the past year. Despite this surge, InvestingPro suggests the stock may be overvalued. The company recently announced a stock offering to raise $100 million, received a reiterated …

Anavex Life Sciences Files Proxy, Urges Director Support

Anavex Life Sciences has filed definitive proxy materials for its 2026 Annual Meeting, urging stockholders to support its six director nominees. This move follows a leadership change and a board refresh effort, with the company highlighting progress on its lead CNS candidate, blarcamesine, and …

MediWound Ltd (MDWD) (Q2 2026) Earnings Call Highlights: Record NexoBrid Sales and EscharEx ...

MediWound Ltd (MDWD) reaffirmed its full-year 2026 revenue guidance, citing strong NexoBrid sales and progress in the EscharEx Phase 3 trial. Despite a Q2 revenue decline and increased operating loss, the company anticipates future growth from the expanded EscharEx market assessment and new agreements. …

PTC Therapeutics’ $211M Bid Wins Bankruptcy Auction for Sangamo Gene Therapy

PTC Therapeutics has won a bankruptcy auction for Sangamo Therapeutics' gene therapy candidate, isaralgagene civaparvovec (ST-920), for Fabry disease, with a bid of $111 million upfront and up to $100 million in milestone payments. This acquisition expands PTC's rare disease pipeline, bringing a therapy …

(VKTX) Price Dynamics and Execution-Aware Positioning

This article provides an analysis of Viking Therapeutics Inc. (NASDAQ: VKTX) price dynamics, highlighting a neutral near-term sentiment that could moderate mid-term weakness. It identifies a mid-channel oscillation pattern and an exceptional short setup with a 50.5:1 risk-reward ratio. The analysis also details institutional …

Contineum Therapeutics (NASDAQ:CTNM) Trading 6.8% Higher - Should You Buy?

Ovid Therapeutics (NASDAQ:OVID) Announces Earnings Results, Beats Estimates By $0.02 EPS

Ovid Therapeutics (NASDAQ:OVID) announced its quarterly earnings, reporting a loss of $0.08 per share, which beat analysts' estimates by $0.02. The company also surpassed revenue expectations, bringing in $0.73 million against a consensus of $0.02 million. Following the positive results, shares of OVID increased …

IN8BIO, Inc. (INAB) investor discloses 9.99% stake and warrant holdings

Laurence W. Lytton and the Lytton-Kambara Foundation have filed an amended ownership report for IN8BIO, Inc. (INAB), indicating a beneficial ownership of 1,056,513 shares, which includes common stock and warrants, representing 9.99% of the company's outstanding shares. This stake is subject to a 9.99% …